MA 16N7C2
Latest Information Update: 30 Dec 1992
At a glance
- Originator Dendreon San Diego LLC
- Class Antithrombotics; Monoclonal antibodies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 30 Dec 1992 Discontinued-Preclinical for Thrombosis in Belgium (Unknown route)
- 30 Dec 1992 Discontinued-Preclinical for Thrombosis in South Africa (Unknown route)
- 30 Dec 1992 Discontinued-Preclinical for Thrombosis in USA (Unknown route)